It is judged safe to discontinue treatment with tyrosine kinase inhibitors for chronic myeloid leukemia in experimental trials on treatment free remission. We collected a total of 293 Italian patients with chronic phase chronic myeloid leukemia who discontinued tyrosine kinase inhibitors in deep molecular response. 72% of patients were on treatment with imatinib, 28% with second generation tyrosine kinase inhibitors at the time of discontinuation. Median duration of treatment with the last tyrosine kinase inhibitor was 77 months (IQR 54;111), median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with tyrosine kinase inhibitors and duration of deep molecular response were shorter with 2nd generation tyrosine kinase inhibitors than with imatinib (p<0.001). 88% of the Italian patients discontinued per clinical practice and reasons for stopping treatment were: toxicity for 20% of patients, pregnancy for 6% patients and shared decision between treating physician and patient for 62% of cases. After a median follow-up of 34 months (Min-Max 12-161) overall estimated treatment free remission was 62% (95% CI 56;68). At 12 months treatment free remission was 68% (95% CI 62;74) for imatinib, 73% (95% CI 64;83) for 2nd generation tyrosine kinase inhibitors. Overall median time to restart treatment was 6 months (IQR 4;11). No progressions occurred. Although our study has the limitation of a retrospective study, our experience within the Italian population confirms that discontinuation of imatinib and 2nd generation tyrosine kinase inhibitors is feasible and safe in the clinical practice.

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice

Fava, Carmen
First
;
Dogliotti, Irene;Cerrano, Marco;Berchialla, Paola;Dragani, Matteo;Giai, Valentina;Ferrero, Dario;Saglio, Giuseppe
Last
2019

Abstract

It is judged safe to discontinue treatment with tyrosine kinase inhibitors for chronic myeloid leukemia in experimental trials on treatment free remission. We collected a total of 293 Italian patients with chronic phase chronic myeloid leukemia who discontinued tyrosine kinase inhibitors in deep molecular response. 72% of patients were on treatment with imatinib, 28% with second generation tyrosine kinase inhibitors at the time of discontinuation. Median duration of treatment with the last tyrosine kinase inhibitor was 77 months (IQR 54;111), median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with tyrosine kinase inhibitors and duration of deep molecular response were shorter with 2nd generation tyrosine kinase inhibitors than with imatinib (p<0.001). 88% of the Italian patients discontinued per clinical practice and reasons for stopping treatment were: toxicity for 20% of patients, pregnancy for 6% patients and shared decision between treating physician and patient for 62% of cases. After a median follow-up of 34 months (Min-Max 12-161) overall estimated treatment free remission was 62% (95% CI 56;68). At 12 months treatment free remission was 68% (95% CI 62;74) for imatinib, 73% (95% CI 64;83) for 2nd generation tyrosine kinase inhibitors. Overall median time to restart treatment was 6 months (IQR 4;11). No progressions occurred. Although our study has the limitation of a retrospective study, our experience within the Italian population confirms that discontinuation of imatinib and 2nd generation tyrosine kinase inhibitors is feasible and safe in the clinical practice.
104
8
1589
1596
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669161/
Chronic Myelogenous Leukemia; Discontinuation; Treatment Free Remission
Fava, Carmen; Rege-Cambrin, Giovanna; Dogliotti, Irene; Cerrano, Marco; Berchialla, Paola; Dragani, Matteo; Rosti, Gianantonio; Castagnetti, Fausto; Gugliotta, Gabriele; Martino, Bruno; Gambacorti-Passerini, Carlo; Abruzzese, Elisabetta; Elena, Chiara; Pregno, Patrizia; Gozzini, Antonella; Capodanno, Isabella; Bergamaschi, Micaela; Crugnola, Monica; Bocchia, Monica; Galimberti, Sara; Rapezzi, Davide; Iurlo, Alessandra; Cattaneo, Daniele; Latagliata, Roberto; Breccia, Massimo; Cedrone, Michele; Santoro, Marco; Annunziata, Mario; Levato, Luciano; Stagno, Fabio; Cavazzini, Francesco; Sgherza, Nicola; Giai, Valentina; Luciano, Luigia; Russo, Sabina; Musto, Pellegrino; Caocci, Giovanni; Sorà, Federica; Iuliano, Francesco; Lunghi, Francesca; Specchia, Giorgina; Pane, Fabrizio; Ferrero, Dario; Baccarani, Michele; Saglio, Giuseppe
File in questo prodotto:
File Dimensione Formato  
FAVA_Haematologica_Open Access_19.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 328.38 kB
Formato Adobe PDF
328.38 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
[PUBLISHED Vsn] Fava et al - Haematologica 2019 - Observational Study - _Open Access_19.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 328.38 kB
Formato Adobe PDF
328.38 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1701468
Citazioni
  • ???jsp.display-item.citation.pmc??? 25
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 37
social impact